 Mohammed Alshareef
Concepts (193)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydrocephalus | 6 | 2024 | 114 | 1.930 |
Why?
| | Cerebral Hemorrhage | 3 | 2023 | 125 | 1.020 |
Why?
| | Braces | 1 | 2026 | 30 | 0.950 |
Why?
| | Fractures, Compression | 1 | 2026 | 21 | 0.950 |
Why?
| | Thoracic Vertebrae | 1 | 2026 | 90 | 0.910 |
Why?
| | Spinal Fractures | 1 | 2026 | 81 | 0.900 |
Why?
| | Lumbar Vertebrae | 1 | 2026 | 259 | 0.820 |
Why?
| | Neurosurgical Procedures | 3 | 2024 | 207 | 0.770 |
Why?
| | Spinal Cord Compression | 2 | 2021 | 24 | 0.770 |
Why?
| | Subdural Space | 1 | 2022 | 7 | 0.730 |
Why?
| | Megalencephaly | 1 | 2022 | 20 | 0.720 |
Why?
| | Intraoperative Care | 1 | 2021 | 63 | 0.640 |
Why?
| | Fasciitis | 1 | 2019 | 11 | 0.580 |
Why?
| | Brain Neoplasms | 3 | 2024 | 1324 | 0.570 |
Why?
| | Pituitary Neoplasms | 1 | 2021 | 190 | 0.570 |
Why?
| | Adenoma | 1 | 2021 | 209 | 0.560 |
Why?
| | Spinal Fusion | 1 | 2021 | 264 | 0.530 |
Why?
| | Head | 1 | 2019 | 125 | 0.520 |
Why?
| | Complement System Proteins | 4 | 2025 | 324 | 0.490 |
Why?
| | Histiocytoma, Malignant Fibrous | 1 | 2016 | 6 | 0.490 |
Why?
| | Craniocerebral Trauma | 1 | 2019 | 173 | 0.490 |
Why?
| | Ultrasonography | 1 | 2021 | 788 | 0.490 |
Why?
| | Craniotomy | 1 | 2016 | 83 | 0.470 |
Why?
| | Models, Theoretical | 2 | 2016 | 558 | 0.360 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 1156 | 0.350 |
Why?
| | Neurosurgery | 2 | 2023 | 39 | 0.350 |
Why?
| | Ventriculoperitoneal Shunt | 2 | 2023 | 44 | 0.350 |
Why?
| | Skull | 3 | 2021 | 162 | 0.320 |
Why?
| | Brain Injuries, Traumatic | 3 | 2021 | 459 | 0.310 |
Why?
| | Tumor Suppressor Proteins | 3 | 2020 | 314 | 0.290 |
Why?
| | Retrospective Studies | 10 | 2026 | 17291 | 0.280 |
Why?
| | Child | 9 | 2026 | 22638 | 0.250 |
Why?
| | Glioblastoma | 2 | 2020 | 349 | 0.250 |
Why?
| | Subdural Effusion | 1 | 2024 | 4 | 0.220 |
Why?
| | Magnetic Resonance Imaging | 4 | 2023 | 3917 | 0.210 |
Why?
| | Neuronavigation | 1 | 2024 | 8 | 0.200 |
Why?
| | Radiography | 1 | 2026 | 856 | 0.200 |
Why?
| | DNA Modification Methylases | 2 | 2020 | 19 | 0.200 |
Why?
| | Humans | 22 | 2026 | 145625 | 0.200 |
Why?
| | DNA Repair Enzymes | 2 | 2020 | 29 | 0.200 |
Why?
| | Drainage | 1 | 2024 | 187 | 0.200 |
Why?
| | Intracranial Pressure | 1 | 2024 | 64 | 0.200 |
Why?
| | Antineoplastic Agents, Alkylating | 2 | 2020 | 76 | 0.190 |
Why?
| | Complement Membrane Attack Complex | 1 | 2023 | 38 | 0.190 |
Why?
| | Child, Preschool | 5 | 2026 | 11888 | 0.190 |
Why?
| | Inflammation | 2 | 2025 | 2915 | 0.180 |
Why?
| | Subarachnoid Space | 1 | 2022 | 8 | 0.180 |
Why?
| | Infant | 5 | 2024 | 10093 | 0.180 |
Why?
| | Hematoma, Subdural | 1 | 2022 | 20 | 0.180 |
Why?
| | Hydroxyapatites | 1 | 2021 | 15 | 0.180 |
Why?
| | Complement Activation | 2 | 2025 | 412 | 0.180 |
Why?
| | Hypertrophy | 1 | 2022 | 126 | 0.170 |
Why?
| | Epidural Space | 1 | 2021 | 17 | 0.170 |
Why?
| | Sample Size | 1 | 2021 | 123 | 0.170 |
Why?
| | Premature Birth | 1 | 2025 | 389 | 0.170 |
Why?
| | Mice | 6 | 2025 | 18266 | 0.160 |
Why?
| | Fetus | 1 | 2025 | 798 | 0.160 |
Why?
| | Iron | 1 | 2023 | 359 | 0.160 |
Why?
| | Internal Fixators | 1 | 2020 | 32 | 0.160 |
Why?
| | Decompression, Surgical | 1 | 2021 | 113 | 0.160 |
Why?
| | Recombinant Fusion Proteins | 1 | 2023 | 662 | 0.160 |
Why?
| | Paraspinal Muscles | 1 | 2020 | 13 | 0.160 |
Why?
| | Female | 11 | 2026 | 79080 | 0.160 |
Why?
| | Operative Time | 1 | 2021 | 192 | 0.150 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2020 | 52 | 0.150 |
Why?
| | Lanosterol | 1 | 2019 | 3 | 0.150 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2020 | 49 | 0.150 |
Why?
| | Surgical Wound | 1 | 2020 | 27 | 0.150 |
Why?
| | Spinal Diseases | 1 | 2020 | 50 | 0.150 |
Why?
| | Central Nervous System Diseases | 1 | 2020 | 73 | 0.150 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2021 | 192 | 0.150 |
Why?
| | Triterpenes | 1 | 2019 | 27 | 0.150 |
Why?
| | Heptanoic Acids | 1 | 2019 | 67 | 0.150 |
Why?
| | Animals, Newborn | 1 | 2022 | 887 | 0.140 |
Why?
| | Neuroprotective Agents | 1 | 2020 | 146 | 0.140 |
Why?
| | Fascia | 1 | 2019 | 19 | 0.140 |
Why?
| | Surgical Flaps | 1 | 2020 | 140 | 0.140 |
Why?
| | Meningioma | 1 | 2019 | 87 | 0.140 |
Why?
| | Meningeal Neoplasms | 1 | 2019 | 95 | 0.140 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 172 | 0.140 |
Why?
| | Neuroimaging | 1 | 2021 | 306 | 0.140 |
Why?
| | Central Nervous System | 1 | 2020 | 278 | 0.130 |
Why?
| | Inflammation Mediators | 1 | 2021 | 507 | 0.130 |
Why?
| | Adolescent | 5 | 2026 | 22451 | 0.130 |
Why?
| | Cohort Studies | 2 | 2026 | 6045 | 0.130 |
Why?
| | Scoliosis | 1 | 2020 | 230 | 0.130 |
Why?
| | Animals | 8 | 2025 | 38030 | 0.130 |
Why?
| | Male | 10 | 2026 | 73014 | 0.130 |
Why?
| | Multivariate Analysis | 1 | 2021 | 1531 | 0.130 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 473 | 0.120 |
Why?
| | Follow-Up Studies | 1 | 2026 | 5397 | 0.120 |
Why?
| | Cranial Fossa, Middle | 1 | 2016 | 17 | 0.120 |
Why?
| | Syndecan-1 | 1 | 2016 | 42 | 0.120 |
Why?
| | Vertebral Artery | 1 | 2016 | 25 | 0.120 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2016 | 66 | 0.120 |
Why?
| | Rats, Sprague-Dawley | 1 | 2022 | 2533 | 0.120 |
Why?
| | Temporal Lobe | 1 | 2016 | 112 | 0.120 |
Why?
| | Prevalence | 1 | 2022 | 2852 | 0.110 |
Why?
| | Cognitive Dysfunction | 1 | 2021 | 479 | 0.110 |
Why?
| | Length of Stay | 1 | 2021 | 1342 | 0.110 |
Why?
| | Finite Element Analysis | 1 | 2014 | 67 | 0.110 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1500 | 0.100 |
Why?
| | Receptors, Cell Surface | 1 | 2016 | 371 | 0.100 |
Why?
| | Disease Progression | 1 | 2022 | 2857 | 0.100 |
Why?
| | Phosphatidylinositol 3-Kinases | 3 | 2020 | 384 | 0.100 |
Why?
| | Treatment Outcome | 2 | 2026 | 11744 | 0.100 |
Why?
| | Rats | 1 | 2022 | 5574 | 0.100 |
Why?
| | Antigens, CD | 1 | 2016 | 559 | 0.100 |
Why?
| | Regional Blood Flow | 1 | 2014 | 507 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1700 | 0.090 |
Why?
| | Spinal Cord | 1 | 2014 | 378 | 0.090 |
Why?
| | Software | 1 | 2014 | 673 | 0.070 |
Why?
| | Reoperation | 2 | 2023 | 633 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 1 | 2019 | 2766 | 0.070 |
Why?
| | Postoperative Complications | 1 | 2021 | 2962 | 0.070 |
Why?
| | Cranial Fontanelles | 1 | 2024 | 4 | 0.050 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2020 | 889 | 0.050 |
Why?
| | Ventriculostomy | 1 | 2024 | 24 | 0.050 |
Why?
| | Middle Aged | 3 | 2021 | 36359 | 0.050 |
Why?
| | Intracranial Hypertension | 1 | 2024 | 42 | 0.050 |
Why?
| | Neurosurgeons | 1 | 2023 | 17 | 0.050 |
Why?
| | P-Selectin | 1 | 2023 | 29 | 0.050 |
Why?
| | Complement Inactivating Agents | 1 | 2023 | 78 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2024 | 278 | 0.040 |
Why?
| | Brain | 2 | 2025 | 2981 | 0.040 |
Why?
| | Lipopolysaccharides | 1 | 2025 | 861 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 676 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2023 | 6021 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2024 | 6449 | 0.040 |
Why?
| | Maze Learning | 1 | 2021 | 105 | 0.040 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 20 | 0.040 |
Why?
| | Cyclin D | 1 | 2020 | 8 | 0.040 |
Why?
| | G1 Phase Cell Cycle Checkpoints | 1 | 2020 | 8 | 0.040 |
Why?
| | Magnetics | 1 | 2020 | 45 | 0.040 |
Why?
| | Smad Proteins | 1 | 2020 | 42 | 0.040 |
Why?
| | Cerebrospinal Fluid Shunts | 1 | 2020 | 35 | 0.040 |
Why?
| | Triazines | 1 | 2020 | 48 | 0.040 |
Why?
| | Equipment Failure | 1 | 2020 | 111 | 0.040 |
Why?
| | Guanine | 1 | 2020 | 85 | 0.040 |
Why?
| | Wnt2 Protein | 1 | 2019 | 1 | 0.040 |
Why?
| | Anaplasia | 1 | 2019 | 7 | 0.040 |
Why?
| | bcl-2-Associated X Protein | 1 | 2019 | 53 | 0.040 |
Why?
| | Data Interpretation, Statistical | 1 | 2021 | 365 | 0.040 |
Why?
| | Sulfones | 1 | 2020 | 127 | 0.040 |
Why?
| | Aminopyridines | 1 | 2020 | 128 | 0.040 |
Why?
| | Benzamides | 1 | 2020 | 226 | 0.040 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2019 | 128 | 0.040 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2019 | 108 | 0.040 |
Why?
| | Imidazoles | 1 | 2020 | 244 | 0.040 |
Why?
| | Benzimidazoles | 1 | 2020 | 189 | 0.040 |
Why?
| | Elective Surgical Procedures | 1 | 2020 | 203 | 0.040 |
Why?
| | Quinolines | 1 | 2020 | 191 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 360 | 0.040 |
Why?
| | Spine | 1 | 2020 | 184 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 334 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2019 | 313 | 0.030 |
Why?
| | Azacitidine | 1 | 2019 | 168 | 0.030 |
Why?
| | Astrocytes | 1 | 2020 | 229 | 0.030 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 299 | 0.030 |
Why?
| | Cell Death | 1 | 2019 | 379 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 2019 | 1041 | 0.030 |
Why?
| | Down-Regulation | 1 | 2019 | 612 | 0.030 |
Why?
| | Cytokines | 1 | 2025 | 2079 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2019 | 438 | 0.030 |
Why?
| | Cell Cycle | 1 | 2020 | 595 | 0.030 |
Why?
| | Research | 1 | 2020 | 421 | 0.030 |
Why?
| | Cell Survival | 1 | 2020 | 1102 | 0.030 |
Why?
| | Adult | 2 | 2020 | 40821 | 0.030 |
Why?
| | Pyrimidines | 1 | 2020 | 530 | 0.030 |
Why?
| | Surgical Wound Infection | 1 | 2020 | 331 | 0.030 |
Why?
| | Sus scrofa | 1 | 2016 | 64 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 446 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2019 | 928 | 0.030 |
Why?
| | Pyrazoles | 1 | 2020 | 516 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2019 | 454 | 0.030 |
Why?
| | Pressure | 1 | 2016 | 221 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2020 | 566 | 0.030 |
Why?
| | Phosphorylation | 1 | 2019 | 1717 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1062 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2019 | 1236 | 0.030 |
Why?
| | DNA Methylation | 1 | 2019 | 721 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2016 | 493 | 0.030 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 868 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2020 | 4112 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2020 | 3538 | 0.020 |
Why?
| | Pregnancy | 1 | 2025 | 7217 | 0.020 |
Why?
| | Neurons | 1 | 2020 | 1663 | 0.020 |
Why?
| | Apoptosis | 1 | 2019 | 2436 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1996 | 0.020 |
Why?
| | Internship and Residency | 1 | 2020 | 1269 | 0.020 |
Why?
| | Aged | 2 | 2020 | 26251 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 6050 | 0.020 |
Why?
| | United States | 1 | 2020 | 16041 | 0.010 |
Why?
|
|
Alshareef's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|